Key result
Platelet cGKI uniquely prevents postischemic platelet adhesion and aggregation in mice.
Answers are grounded in this paper and cite their sources.
Atherosclerotic vascular lesions are considered to be a major cause of ischemic diseases, including myocardial infarction and stroke. Platelet adhesion and aggregation during ischemia-reperfusion are thought to be the initial steps leading to remodeling and reocclusion of the postischemic vasculature. Nitric oxide (NO) inhibits platelet aggregation and smooth muscle proliferation. A major downstream target of NO is cyclic guanosine 3', 5'-monophosphate kinase I (cGKI). To test the intravascular significance of the NO/cGKI signaling pathway in vivo, we have studied platelet-endothelial cell and platelet-platelet interactions during ischemia/reperfusion using cGKI-deficient (cGKI-/-) mice. Platelet cGKI but not endothelial or smooth muscle cGKI is essential to prevent intravascular adhesion and aggregation of platelets after ischemia. The defect in platelet cGKI is not compensated by the cAMP/cAMP kinase pathway supporting the essential role of cGKI in prevention of ischemia-induced platelet adhesion and aggregation.
No takes yet. Share an insight, caveat, or question.
Maßberg et al. (1999) studied Ischemia-reperfusion. cGKI deficiency was evaluated on Intravascular adhesion and aggregation of platelets after ischemia. cGKI deficiency in mice revealed that platelet cGKI, but not endothelial or smooth muscle cGKI, is essential to prevent intravascular adhesion and aggregation of platelets after ischemia.
Synapse has enriched 10 related papers. Consider them for comparative context: